The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
Abstract
OBJECTIVES: To assess the safety and effect on coagulopathy of a range of doses of recombinant human activated protein C (rhAPC). To determine an effective dose and duration of rhAPC for use in future clinical trials. DESIGN: Double-blind, randomized, placebo-controlled, multicenter, dose-ranging (sequential), phase II clinical trial. SETTING: Forty community or academic medical institutions in United States and Canada. PATIENTS: One hundred thirty-one adult patients with severe sepsis. INTERVENTIONS: Intravenous infusion of rhAPC (12, 18, 24, or 30 microg/kg/hr) or placebo for 48 or 96 hrs. MEASUREMENTS AND MAIN RESULTS: No significant differences in incidence of serious bleeding events (4% rhAPC, 5% placebo, p >.999) or incidence of serious adverse events (39% rhAPC, 46% placebo, p = 0.422) between rhAPC- and placebo-treated patients were observed. One of 53 rhAPC-treated patients with suitable immunogenicity samples had a low level, transient, non-neutralizing anti-APC antibody response not associated with any clinical adverse event. Significant dose-dependent decreases in both D-dimer (p <0.001) and end of infusion interleukin 6 levels (p =.021) were demonstrated. No statistically significant effects on fibrinogen or platelet counts were observed. A nonstatistically significant 15% relative risk reduction in 28-day all-cause mortality was observed between rhAPC- and placebo-treated patients. CONCLUSIONS: rhAPC was safe and well-tolerated and demonstrated a dose-dependent reduction in D-dimer and interleukin 6 levels relative to placebo. The dose of 24 microg/kg/hr for 96 hrs was selected for use in future clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Harada, N., Johno, M., & Naruo, M. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01393.1998 · Cited by 116
RetractedAPACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
(2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421801 · Cited by 12,941
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
Rangel-Frausto, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.117 · Cited by 2,104
Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J., Eisenberg, P. R., & Miletich, J. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321403 · Cited by 1,035
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Self-citationvan Deventer, S., Buller, H., ten Cate, J., Aarden, L., Hack, C., & Sturk, A. (1990) · Blood · doi:10.1182/blood.v76.12.2520.2520 · Cited by 851
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
Taylor, F. B., Chang, A., Esmon, C. T., D'Angelo, A., Vigano-D'Angelo, S., & Blick, K. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112902 · Cited by 821
Cited by
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
Dellinger, R. P., Carlet, J. M., Masur, H., Gerlach, H., Calandra, T., Cohen, J., Gea-Banacloche, J., Keh, D., Marshall, J. C., Parker, M. M., et al. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2210-z · Cited by 3,321
Sepsis in European intensive care units: Results of the SOAP study*
Vincent, J.-L., Sakr, Y., Sprung, C. L., Ranieri, V. M., Reinhart, K., Gerlach, H., Moreno, R., Carlet, J., Le Gall, J.-R., & Payen, D. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000194725.48928.3a · Cited by 2,836
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202290 · Cited by 1,309
Metadata
- Authors
- Bernard, G. R., Ely, E. W., Wright, T. J., Fraiz, J., Stasek, J. E., Russell, J. A., Mayers, I., Rosenfeld, B. A., Morris, P. E., Yan, S. B., & Helterbrand, J. D.
- Venue
- Critical Care Medicine
- Published
- 2001-11
- Volume
- 29
- Issue
- 11
- Pages
- 2051-2059
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W1980233581
- Cited by
- 271
- References
- 48
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. https://app.cochat.ai/papers/10.1097/00003246-200111000-00003
- The paper
- Bernard, G. R., Ely, E. W., Wright, T. J., Fraiz, J., Stasek, J. E., Russell, J. A., Mayers, I., Rosenfeld, B. A., Morris, P. E., Yan, S. B., & Helterbrand, J. D. (2001). Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Critical Care Medicine. https://doi.org/10.1097/00003246-200111000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.